Legislator Giurisprudenza & Legislazione
ln_2010_21 MT

Reg. 2 — Regulations, 2010

Malta Government Gazette — Legal Notice 2010 21 — Regulations, 2010
Apri la fonte ufficiale Atto completo (4 Articoli) Versione Markdown leggibile dalle macchine (.md)

Reg. 2 · Regulations, 2010

Schedule XI to the principal regulations shall be Substitutes

Schedule XI to

substituted by the following

the principal

regulations.

* OJ L.39, 10-02-2009, p.34.

** OJ L.131, 16-05-2002, p.17.

"Schedule XI

Based on Annex I of Commission Decision 2009/108/EC of 3 February 2009 on

common technical specifications (CTS) for in vitro diagnostic medical devices

1. SCOPE

The common technical specifications set out in this Schedule shall apply

for the purposes of Schedule II, List A.

2. DEFINITIONS AND TERMS

(Diagnostic) sensitivity

The probability that the device gives a positive result in the presence of

the target marker.

True positive A specimen known to be positive for the target marker

and correctly classified by the device.

False negative A specimen known to be positive for the target marker

and misclassified by the device.

(Diagnostic) specificity The probability that the device gives a negative

result in the absence of the target marker.

False positive

A specimen known

to be negative for the target marker and

misclassified by the device.

True negative

A specimen known to be negative for the target marker and correctly

classified by the device.

Analytical sensitivity

Analytical sensitivity may be expressed as the limit of detection, i.e. the

smallest amount of the target marker that can be precisely detected.

Analytical specificity

Analytical specificity means the ability of the method to determine

solely the target marker.

Nucleic acid amplification techniques (NAT)

The term ‘NAT’ is used for tests for the detection and/or quantification

of nucleic acids by either amplification of a target sequence, by amplification

of a signal or by hybridisation.

Rapid test

‘Rapid test’ means qualitative or semi quantitative in vitro diagnostic

medical devices, used singly or in a small series, which involve non-

automated procedures and have been designed to give a fast result.

Robustness

The robustness of an analytical procedure means the capacity of an analytical

procedure to remain unaffected by small but deliberate variations in method

parameters and provides an indication of its reliability during normal usage.

Whole system failure rate

The whole system failure rate means the frequency of failures when the

entire process is performed as prescribed by the manufacturer.

Confirmation assay

Confirmation assay means an assay used for the confirmation of a reactive

result from a screening assay.

Virus typing assay

Virus typing assay means an assay used for typing with already known

positive samples, not used for primary diagnosis of infection or for screening.

Sero-conversion HIV samples

Sero-conversion HIV samples mean

-

p24 antigen and/or HIV RNA positive and;

-

recognised by all of the antibody screening tests and;

-

positive or indeterminate confirmatory assays.

Early sero-conversion HIV samples

Early sero-conversion HIV samples mean

-

p24 antigen and/or HIV RNA positive and;

-

not recognised by all of the antibody screening tests and;

-

indeterminate or negative confirmatory assays.

← Reg. 1 Regulations, 2010 Reg. 3 →

Ti chiedi come si applica questa disposizione alla tua fattispecie?

Analizza questa norma insieme alla giurisprudenza, ai commentari e alle disposizioni correlate in Legislator AI.

Apri in Legislator →